Immune Modulation by Exosomes in COVID-19
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversity of Ulm
About this trial
Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.
Eligibility criteria
Qualifiers
Critically ill COVID-19 patients with lung dysfunction
COVID-19 WHO severity degree >= 4, ARDS (WHO Definition 13 March 2020)
Body weight > 50 kg
Informed consent
Disqualifiers
Pregnant or breast feeding women
Trial design
Treatments tested in this trial
- Application of exosomes in a whole blood assay
Treatment groups
No treatment groups listed
Locations
1Ulm University Hospital, Clinic of Anesthesiology and Intensive Care Medicine89070, Ulm Germany
Sponsors and collaborators
University of Ulm
Lead sponsor
Source ClinicalTrials.gov